Guardant Health (NASDAQ:GH) Director Sells $133,862.50 in Stock

Guardant Health, Inc. (NASDAQ:GH) Director Medina Manuel Hidalgo sold 1,250 shares of the firm’s stock in a transaction dated Wednesday, May 20th. The shares were sold at an average price of $107.09, for a total value of $133,862.50. Following the sale, the director owned 1,639 shares in the company, valued at $175,520.51. This trade represents a 43.27% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Medina Manuel Hidalgo also recently made the following trade(s):

• On Friday, March 6th, Medina Manuel Hidalgo sold 1,300 shares of Guardant Health stock. The stock was sold at an average price of $91.54, for a total value of $119,002.00.

Guardant Health Price Performance

GH stock traded up $0.94 during mid-day trading on Friday, reaching $118.95. 2,633,856 shares of the company’s stock were exchanged, compared to its average volume of 2,090,416. The company has a market cap of $15.77 billion, a price-to-earnings ratio of -35.09 and a beta of 1.48. The stock’s 50 day moving average is $90.53 and its 200 day moving average is $98.79. Guardant Health, Inc. has a 12-month low of $36.36 and a 12-month high of $121.01.

Guardant Health (NASDAQ:GH) last posted its quarterly earnings data on Thursday, February 19th. The company reported ($0.50) EPS for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.07). The firm had revenue of $281.27 million during the quarter, compared to analyst estimates of $269.74 million. Guardant Health’s quarterly revenue was up 39.4% on a year-over-year basis. During the same period in the previous year, the business earned ($0.62) EPS. On average, research analysts forecast that Guardant Health, Inc. will post -2.92 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts recently commented on GH shares. BTIG Research boosted their price target on shares of Guardant Health from $140.00 to $145.00 and gave the stock a “buy” rating in a report on Friday, February 20th. TD Cowen reiterated a “buy” rating on shares of Guardant Health in a research report on Thursday. Robert W. Baird began coverage on shares of Guardant Health in a research note on Tuesday, February 17th. They set an “outperform” rating and a $120.00 target price for the company. Canaccord Genuity Group upped their price target on shares of Guardant Health from $125.00 to $135.00 and gave the stock a “buy” rating in a research report on Friday, February 20th. Finally, Guggenheim lifted their price objective on Guardant Health from $115.00 to $135.00 and gave the stock a “buy” rating in a report on Monday, January 26th. Nineteen analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Guardant Health has an average rating of “Moderate Buy” and an average price target of $129.00.

Institutional Investors Weigh In On Guardant Health

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Alyeska Investment Group L.P. acquired a new stake in shares of Guardant Health in the third quarter valued at about $114,421,000. Price T Rowe Associates Inc. MD boosted its position in Guardant Health by 33.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 5,636,078 shares of the company’s stock worth $575,670,000 after acquiring an additional 1,414,441 shares during the last quarter. Norges Bank purchased a new stake in Guardant Health during the 4th quarter valued at about $128,499,000. Summit Partners Public Asset Management LLC grew its stake in Guardant Health by 674.5% during the 4th quarter. Summit Partners Public Asset Management LLC now owns 851,958 shares of the company’s stock valued at $87,019,000 after acquiring an additional 741,958 shares in the last quarter. Finally, Franklin Resources Inc. raised its holdings in Guardant Health by 26.1% in the 3rd quarter. Franklin Resources Inc. now owns 2,926,315 shares of the company’s stock valued at $182,836,000 after acquiring an additional 606,368 shares during the last quarter. Institutional investors and hedge funds own 92.60% of the company’s stock.

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.